> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Senseonics Raises Sales Outlook On U.S. Eversense Growth — But Its Quarterly Loss Widens
- URL: https://www.bullished.co/senseonics-raises-sales-outlook-on-u-s-eversense-growth-but-its-quarterly-loss-widens-a60c467c/
- Published: 2026-11-09T21:21:13.000Z
- Updated: 2026-11-09T21:21:13.000Z
- Description: Revenue rose approximately 140%, while spending on the commercial organization and new monitors increased.
- Author: Matteo Parrino
- Tags: Earnings, SENS, Industry: Healthcare

Senseonics Holdings, which sells implantable glucose monitors for people with diabetes, raised its 2026 sales forecast Monday to [$68 million–$70 million](https://www.globenewswire.com/news-release/2026/11/09/3398953/0/en/senseonics-holdings-inc-reports-third-quarter-2026-financial-results.html?ref=bullished.co) from $62 million–$66 million as U.S. Eversense 365 growth outpaced expectations. The earnings release accompanying its SEC filing also showed a wider quarterly loss: $32.7 million, compared with $19.5 million a year earlier.

## U.S. Sales Lead The Upgrade

Third-quarter revenue rose approximately 140% to [$19.6 million](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926124500/sens-ex99d1.htm?ref=bullished.co), versus $8.1 million a year earlier. U.S. sales accounted for $16.8 million, up approximately 160% from $6.4 million, with shipment volume reaching a quarterly record and active prescribers increasing approximately 90%.

Outside the U.S., sales reached $2.8 million, approximately 65% higher than the prior year's $1.7 million. Because U.S. growth has exceeded expectations, management now expects international markets to supply approximately 15% of annual revenue.

The revised annual sales range implies growth of 93%–98%. Senseonics also raised its forecast for gross margin—the share of revenue left after product costs—to more than 60%, replacing a 58%–61% range. Its outlook includes consumer marketing, patient assistance programs and the continuing European rollout.

## Better Margins, A Bigger Loss

Gross profit reached [$12.1 million](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926124500/sens-ex99d1.htm?ref=bullished.co), compared with $3.5 million a year earlier. Approximately 62% of sales remained after product costs, versus 43%.

Commercial expansion came with substantially higher expenses. Selling and administrative costs reached $32.3 million, versus $15.3 million, which Senseonics attributed to running its U.S. and European commercial organization. Research and development costs were $11.7 million, up from $7.8 million, with management citing Gemini clinical trials and Freedom development.

The quarterly loss per share was $0.50, compared with $0.43\. For the first nine months, revenue totaled $45.8 million versus $21.0 million, while net losses reached $101.7 million versus $48.3 million.

At September 30, Senseonics held $126.6 million across cash, restricted cash, cash equivalents and short-term investments. Its Hercules Capital debt had a carrying value of approximately $56.2 million, with $55.0 million of principal outstanding, consistent with the second quarter.

## More Inserters And Pump Connections

[Senseonics now controls its commercial operations](https://www.globenewswire.com/news-release/2026/11/09/3398953/0/en/senseonics-holdings-inc-reports-third-quarter-2026-financial-results.html?ref=bullished.co) globally, including teams leading European Eversense 365 launches. The system pairs an implanted sensor with a removable transmitter and a phone app; the sensor monitors glucose for up to twelve months.

The EON Care network has more than 100 inserters, who handled over 40% of quarterly insertion procedures. Senseonics raised its year-end target to 120.

“Recent investments in commercial infrastructure are expanding patient access, supporting our growth and improving gross margins,” Senseonics President and CEO Tim Goodnow said in the [earnings release](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926124500/sens-ex99d1.htm?ref=bullished.co).

Its existing Sequel partnership connects Eversense 365 with the twiist automated insulin-delivery system. Senseonics also announced a Beta Bionics partnership to connect the monitor with the iLet Bionic Pancreas insulin-delivery system, and started human testing of Freedom, an investigational monitor designed to communicate with phones without an on-body component.

Senseonics plans to launch the Beta Bionics integration commercially in the fourth quarter of 2026, pending completion of integration work and applicable requirements.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Senseonics Holdings, Inc. (SENS)](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926124500/sens-20261109x8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit sens-ex99d1.htm — Senseonics Holdings, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926124500/sens-ex99d1.htm?ref=bullished.co) — SEC EDGAR
- [Senseonics Holdings, Inc. Reports Third Quarter 2026](https://www.globenewswire.com/news-release/2026/11/09/3398953/0/en/senseonics-holdings-inc-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com